Paul Noble is a Respiratory physician affiliated with Cedars-Sinai Medical Center. OpenAlex indexes 336 publications with 46,557 citations (h-index 97). By OpenAlex citation count, this profile ranks in the top 5% of Pulmonary Disease profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
8700 Beverly Blvd Ste 2119
West Hollywood, CA 900481804
Telephone
310-423-1888Provider last certified this registry record 25 Sept 2020.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20257 payments$21,218openpaymentsdata.cms.gov ↗
- GlaxoSmithKline, LLC.Program year20259 payments$20,424openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
8 NIH research awards on record, funded 2012–2026 per NIH RePORTER. The latest:
- ZIP8-dependent Zinc Metabolic Regulation in Alveolar Progenitor Cell Aging and Fibrosis
Cedars-Sinai Medical Center
FY2026$544,545R01AG078655 - Molecular Regulation of Progressive Pulmonary Fibrosis
Cedars-Sinai Medical Center
FY2025$847,538R35HL150829 - ZIP8-dependent Zinc Metabolic Regulation in Alveolar Progenitor Cell Aging and Fibrosis
Cedars-Sinai Medical Center
FY2025$533,653R01AG078655
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Senescence of Alveolar Type 2 Cells Drives Progressive Pulmonary Fibrosis
American Journal of Respiratory and Critical Care Medicine
2020 - Alveolar Epithelial Type II Cells as Drivers of Lung Fibrosis in Idiopathic Pulmonary Fibrosis
International Journal of Molecular Sciences
2020 - Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis
Science Translational Medicine
2019 - Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis
The Lancet Respiratory Medicine
2016
Similar KOLs
Other experts from the same institution or the same specialty.
Beth Karlan, MD
Cedars-Sinai Medical Center
Raj Makkar, MD
Cedars-Sinai Medical Center
Stephen Freedland, MD
Cedars-Sinai Medical Center
Jon Kobashigawa, MD
Cedars-Sinai Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”